China’s Bloomage Biotech Set To Produce Exportable Medical Products
This article was originally published in PharmAsia News
Executive SummaryBloomage Biotechnology, a new biotech in China, is set to begin producing injectable hyaluronic acid in October and apply for its U.S. FDA approval for medical uses. Bloomage is the sole company licensed in mainland China to sell the chemical for medical use. Hyaluronic acid is considered equivalent to botox and is used primarily in cosmetics, but about 25 percent of Bloomage sales come from products with medical applications. The firm conducted clinical trials of hyaluronic acid products over the past year. (Click here for more
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.